CAR-NK Cell Therapy for Advanced Head and Neck Cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new type of cell therapy using natural killer cells (immune cells) that are designed to recognize and attack head and neck cancer cells. The therapy targets two specific proteins (EGFR and HER2) found on cancer cells and is for patients whose cancer has returned or spread despite previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Squamous cell carcinoma (a type of head and neck cancer) in the mouth, throat, or voice box that has returned or spread and cannot be surgically removed or treated with radiation
- Cancer cells must show specific markers (EGFR and HER2) on testing
- Cancer has progressed despite at least one prior chemotherapy or immunotherapy treatment
- Adequate organ function (heart, lungs, kidneys, liver) based on blood tests and imaging
- Willingness to provide tumor tissue for testing and undergo regular blood draws and optional biopsies
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy using specially engineered natural killer cells (a type of immune cell) designed to target two proteins found on esophageal cancer cells. It's for patients with advanced esophageal adenocarcinoma that has spread or returned after prior treatment.
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets specific proteins on breast cancer cells. It's for people with advanced HER2-positive or triple-negative breast cancer who have tried other treatments or can't take them.
This trial tests whether specially engineered NK cells can find and attack your type of cancer. It is for people with advanced solid tumors that haven't responded to standard treatments.
This study tests a new type of immune cell therapy (CAR-NK cells) designed to recognize and attack lung cancer cells that have spread or stopped responding to standard treatments. The goal is to see if this approach can shrink tumors and help patients live longer.
This trial tests a new type of cell therapy (CAR-NK cells) designed to attack gastric and esophageal junction cancers that have specific markers on their surface. The cells are engineered to recognize two targets on your cancer cells, which may help your immune system fight the cancer more effectively.
This trial tests a new type of immune cell therapy (CAR-NK cells) designed to fight advanced colorectal cancer that has spread or cannot be surgically removed. The therapy is customized to target specific protein markers on your cancer cells.
Hear when a new Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.